Galapagos Announced New Results From Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma; Demonstrated High Antitumor Activity And An Encouraging Safety Profile In All NHL Subtypes Studied
Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate efficacy and safety profile in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Most patients in the study received GLPG5101 as a fresh, fit, stem-like, early memory CD19 CAR T-cell therapy, with a median vein-to-vein time of seven days.
- Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.
- 96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy.
- These data reinforce the potential of Galapagos' decentralized cell therapy manufacturing platform to deliver fresh, fit cells, fast, driving positive patient outcomes.
